⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Lumanity and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Lumanity
↗Morristown, New Jersey, USA
Lumanity is a global life sciences consulting firm that provides end-to-end commercialization support to pharmaceutical and biotechnology companies. The company helps clients navigate complex healthcare landscapes by blending scientific, clinical, medical, regulatory, and commercial expertise with advanced technology and AI-driven insights.
Formed in 2022 through the merger of several specialized firms—including Cello Health, BresMed, Guidemark Health, Cyan Health, and Zipher Medical Affairs—Lumanity focuses on accelerating patient access to medical advances. They support clients across the product lifecycle, from early-stage development and regulatory strategy to launch excellence and real-world evidence generation.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:~$130M
Founded:2020
Ownership:private
Status:operating
FUNDING
Investors:Arsenal Capital Partners
PIPELINE
Modalities:Small molecule, Cell therapy, Gene therapy, Biologics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:BresMed Health Solutions, Cello Health, Guidemark Health, Zipher Medical Affairs, Cyan Health, Clarion Healthcare
Key Partnerships:Works with 150+ top pharmaceutical and 100+ biotech companies globally.
COMPETITION
Position:Leader
Competitors:IQVIA, Syneos Health, Parexel, ClearView Healthcare Partners, Trinity Life Sciences
LEADERSHIP
Key Executives:
Jon Williams - CEO
LINKS
Website:lumanity.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Lumanity. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.